Is Arvinas, Inc. (ARVN) a Buy, Sell, or Hold?
Arvinas, Inc.
NASDAQ:ARVN
$26.72 USD
$0.74 (2.85%)
- Volume
- 304.08K
- Average Volume
- 571.39K
- Market Capitalization
- $1.84B
- P/E Ratio
- -6.24
- Dividend Yield
- 0.00%
- Price Target
- $66.50
- Year High
- $53.08
- Year Low
- $21.17
- Payout Ratio
- $0.00
- Current Ratio
- $4.17
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. John G. Houston Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ARVN |
| CUSIP | 04335A105 |
| CIK | 0001655759 |
| Web | https://www.arvinas.com |
| Phone | 203 535 1456 |
| Currency | USD |
| Employees | 445 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.17 |
| Quick Ratio | 4.17 |
| Cash Ratio | 0.31 |
Sales & Book Value
| Annual Sales | $78.5M |
| Price / Sales | 11.40 |
| Cash Flow | -3.60 |
| Price / Cash Flow | -7.06 |
| Price / Book | 3.29 |
Price Target and Rating
| Average Stock Price Forecast | $66.50 |
| High Stock Price Forecast | $123.00 |
| Low Stock Price Forecast | $24.00 |
| Forecast Upside/Downside | -59.82% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.62 |
| Trailing P/E Ratio | -6.24 |
| PEG Ratio | -0.65 |
| P/E Growth | -0.65 |
| Net Income | $-367.3M |
| Net Margin | -191.56% |
| Pretax Margin | -190.01% |
| Return on Equity | -50.26% |
| Return on Assets | -26.44% |
Financials Score
| AltmanZ Score | 0.14 |
| Piotroski Score | 4.00 |
| Working Capital | 873.6M |
| Total Assets | 1.17B |
| Ebit | -357.4M |
| Market Cap | 1.84B |
| Total Liabilities | 581.1M |
Poll Results
About Arvinas, Inc. (NASDAQ:ARVN) Stock
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La ... Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
2024-11-29 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
2024-11-29 08:00:00
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.
2024-11-28 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
2024-11-27 12:00:00
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2024-11-27 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Frequently Asked Questions
-
What is the current Arvinas, Inc. (ARVN) stock price?
-
Arvinas, Inc.(NASDAQ:ARVN) stock price is $26.72 in the last trading session. During the trading session, ARVN stock reached the peak price of $53.08 while $21.17 was the lowest point it dropped to. The percentage change in ARVN stock occurred in the recent session was 2.85% while the dollar amount for the price change in ARVN stock was $0.74.
-
ARVN's industry and sector of operation?
-
The NASDAQ listed ARVN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARVN?
-
Dr. Ian Taylor Ph.D. | President of Research & Development and Chairman of Scientific Advisory Board
Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer
Mr. Steve Weiss | Senior Vice President & Chief Human Resources Officer
Mr. Paul McInulty | Senior Vice President of Regulatory Affairs
Mr. Andrew R. Saik | Chief Financial Officer & Treasurer -
How many employees does ARVN have?
-
Number of ARVN employees currently stands at 445. ARVN operates from 5 Science Park, New Haven, CT 06511, US.
-
Link for ARVN official website?
-
Official Website of ARVN is: https://www.arvinas.com
-
How do I contact ARVN?
-
ARVN could be contacted at phone #203 535 1456 and can also be accessed through its website. ARVN operates from 5 Science Park, New Haven, CT 06511, US.
-
How many shares of ARVN are traded daily?
-
The average number of ARVN shares traded daily for last 3 months was 571.39K.
-
What is the market cap of ARVN currently?
-
The market value of ARVN currently stands at $1.84B with its latest stock price at $26.72